Federated Hermes
TVRD

Federated Hermes’s Tvardi Therapeutics TVRD Stock Holding History

Federated Hermes’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-133
Closed -$1.48K – 2209
2024
Q3 		$1.48K Sell
133
-205
-61% -$2.4K ﹤0.01% 1955
2024
Q2 		$3.13K Sell
338
-3
-0.9% -$72 ﹤0.01% 1876
2024
Q1 		$11.2K Sell
341
-22,766
-99% -$590K ﹤0.01% 1768
2023
Q4 		$618K Buy
23,107
+788
+4% +$32.6K ﹤0.01% 1290
2023
Q3 		$1.35M Sell
22,319
-179
-0.8% -$16.8K ﹤0.01% 1022
2023
Q2 		$2.29M Buy
22,498
+17,377
+339% +$2.39M 0.01% 911
2023
Q1 		$905K Buy
+5,121
New +$1.71M ﹤0.01% 1197
2022
Q3 		– Sell
-89
Closed -$29K – 2259
2022
Q2 		$29K Sell
89
-78
-47% -$27.4K ﹤0.01% 1733
2022
Q1 		$73K Buy
167
+36
+27% +$14.8K ﹤0.01% 1693
2021
Q4 		$57K Sell
131
-178
-58% -$89.4K ﹤0.01% 1777
2021
Q3 		$172K Sell
309
-49
-14% -$24.6K ﹤0.01% 1693
2021
Q2 		$184K Buy
+358
New +$227K ﹤0.01% 1687
2019
Q4 		– Sell
-2,924
Closed -$1.92M – 2320
2019
Q3 		$1.92M Buy
2,924
+2,918
+48,633% +$2.43M ﹤0.01% 1046
2019
Q2 		$5K Buy
+6
New +$4.22K ﹤0.01% 1996
2019
Q1 		– Sell
-1,544
Closed -$723K – 2242
2018
Q4 		$723K Sell
1,544
-1,051
-41% -$678K ﹤0.01% 1367
2018
Q3 		$2.24M Buy
2,595
+2,590
+51,800% +$1.87M 0.01% 1050
2018
Q2 		$3K Buy
+5
New +$2.54K ﹤0.01% 2082
2018
Q1 		– Sell
-1,085
Closed -$478K – 2244
2017
Q4 		$478K Sell
1,085
-18
-2% -$8.21K ﹤0.01% 1389
2017
Q3 		$543K Sell
1,103
-539
-33% -$270K ﹤0.01% 1344
2017
Q2 		$910K Sell
1,642
-25
-1% -$15.9K ﹤0.01% 1240
2017
Q1 		$1.1M Buy
+1,667
New +$891K ﹤0.01% 1144
2016
Q1 		– Hold
0
– -$1K – 2183
2015
Q4 		– Sell
-331
Closed -$182K – 2038
2015
Q3 		$170K Buy
331
+324
+4,629% +$217K ﹤0.01% 1519
2015
Q2 		$3K Buy
+7
New +$2.71K ﹤0.01% 1851

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes's TVRD Position: Q4 2024 in Review

Federated Hermes sold out of Tvardi Therapeutics (TVRD) in Q4 2024, closing a stake of 133 shares — an estimated $1.48K sold.

Federated Hermes first reported a position in TVRD in Q2 2015 and held it in 23 quarters. The position peaked at $2.29M in Q2 2023. 43 funds tracked by Wall St. Rank hold TVRD as of Q4 2024.

  • Federated Hermes reported no remaining Tvardi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Federated Hermes sold 133 Tvardi Therapeutics shares in Q4 2024, an estimated $1.48K.
  • Federated Hermes first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 23 quarters.
  • Federated Hermes's Tvardi Therapeutics position peaked at $2.29M in Q2 2023.
  • 43 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2024.

Based on Federated Hermes's 13F filing for Q4 2024, filed 13 Feb 2025.